The Effect of Door-to-Diuretic Time on Clinical Outcomes in Patients With Acute Heart Failure.

[1]  R. Matsukawa,et al.  Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. , 2017, Journal of the American College of Cardiology.

[2]  G. Felker,et al.  Door-to-Furosemide Therapy in the ED: New Quality Metric or Just a Piece of the Puzzle? , 2017, Journal of the American College of Cardiology.

[3]  M. Cho,et al.  Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF) , 2017, Korean circulation journal.

[4]  P. Ponikowski,et al.  Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure , 2017, The New England journal of medicine.

[5]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[6]  P. Ponikowski,et al.  Recommendations on pre‐hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine , 2015, European journal of heart failure.

[7]  Y. Ahn,et al.  A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry , 2014, European journal of heart failure.

[8]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[9]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[10]  L. Deckelbaum,et al.  Effect of nesiritide in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[11]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[12]  Li Liang,et al.  A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines Program , 2010, Circulation. Cardiovascular quality and outcomes.

[13]  C. Yancy,et al.  Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). , 2007, American heart journal.

[14]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[15]  Harlan M Krumholz,et al.  Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. , 2006, Journal of the American College of Cardiology.

[16]  L. Rydén,et al.  Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. , 2003, Journal of the American College of Cardiology.

[17]  C. Gibson,et al.  Time is myocardium and time is outcomes. , 2001, Circulation.

[18]  C M Gibson,et al.  Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. , 2000, JAMA.